P042 | PU.1 as master regulator of acute myeloid leukemia venetoclax resistance
Introduction. Venetoclax-based therapies have improved outcomes in acute myeloid leukemia (AML), especially in elderly or unfit patients. However, resistance remains a major limitation. Recent studies suggest that monocytic differentiation (FAB M4/M5) is associated with reduced venetoclax sensitivi...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Ferrata Storti Foundation
2026-03-01
|
| Serie: | Haematologica |
| Accesso online: | https://haematologica.org/article/view/13306 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|